Aerovate Therapeutics AVTE Stock
25.24 USD
{{ price }}
-6.136109%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
703.26M USD
LOW - HIGH [24H]
24.57
-
27.11 USD
VOLUME [24H]
133.11K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.87 USD
Aerovate Therapeutics Price Chart
Aerovate Therapeutics AVTE Financial and Trading Overview
| Aerovate Therapeutics stock price | 25.24 USD |
| Previous Close | 16.94 USD |
| Open | 17.07 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1100 |
| Day's Range | 16.73 - 17.07 USD |
| 52 Week Range | 11.41 - 30.79 USD |
| Volume | 89.77K USD |
| Avg. Volume | 82.89K USD |
| Market Cap | 421.21M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.87 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33 USD |
AVTE Valuation Measures
| Enterprise Value | 304.25M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.4503818 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.70858 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.09 |
Trading Information
Aerovate Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 38.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 30.79 USD |
| 52 Week Low | 11.41 USD |
| 50-Day Moving Average | 18.63 USD |
| 200-Day Moving Average | 20.7 USD |
AVTE Share Statistics
| Avg. Volume (3 month) | 82.89K USD |
| Avg. Daily Volume (10-Days) | 130.68K USD |
| Shares Outstanding | 24.92M |
| Float | 7.33M |
| Short Ratio | 14.12 |
| % Held by Insiders | 0.24% |
| % Held by Institutions | 110.38% |
| Shares Short | 961.9K |
| Short % of Float | 7.45% |
| Short % of Shares Outstanding | 3.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.67% |
| Return on Equity (ttm) | -41.53% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -59779000 USD |
| Net Income Avi to Common (ttm) | -57121000 USD |
| Diluted EPS (ttm) | -2.26 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 118.93M USD |
| Total Cash Per Share (mrq) | 4.77 USD |
| Total Debt (mrq) | 964K USD |
| Total Debt/Equity (mrq) | 0.85 USD |
| Current Ratio (mrq) | 11.335 |
| Book Value Per Share (mrq) | 4.557 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -44885000 USD |
| Levered Free Cash Flow (ttm) | -21752624 USD |
Profile of Aerovate Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 930 Winter Street |
| ZIP | 02451 |
| Phone | 617 443 2400 |
| Website | https://aerovatetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 43 |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Q&A For Aerovate Therapeutics Stock
What is a current AVTE stock price?
Aerovate Therapeutics AVTE stock price today per share is 25.24 USD.
How to purchase Aerovate Therapeutics stock?
You can buy AVTE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aerovate Therapeutics?
The stock symbol or ticker of Aerovate Therapeutics is AVTE.
Which industry does the Aerovate Therapeutics company belong to?
The Aerovate Therapeutics industry is Biotechnology.
How many shares does Aerovate Therapeutics have in circulation?
The max supply of Aerovate Therapeutics shares is 27.86M.
What is Aerovate Therapeutics Price to Earnings Ratio (PE Ratio)?
Aerovate Therapeutics PE Ratio is now.
What was Aerovate Therapeutics earnings per share over the trailing 12 months (TTM)?
Aerovate Therapeutics EPS is -2.87 USD over the trailing 12 months.
Which sector does the Aerovate Therapeutics company belong to?
The Aerovate Therapeutics sector is Healthcare.
Aerovate Therapeutics AVTE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}